Purple Biotech (PPBT) Stock Overview
A clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PPBT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Purple Biotech Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪4.29 |
| 52 Week High | ₪29.40 |
| 52 Week Low | ₪3.60 |
| Beta | -0.74 |
| 1 Month Change | 0.94% |
| 3 Month Change | -34.75% |
| 1 Year Change | -84.00% |
| 3 Year Change | -98.89% |
| 5 Year Change | -99.49% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| PPBT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.6% | 2.9% | -0.3% |
| 1Y | -84.0% | 29.1% | 16.1% |
Return vs Industry: PPBT underperformed the US Pharmaceuticals industry which returned 28.1% over the past year.
Return vs Market: PPBT underperformed the US Market which returned 16% over the past year.
Price Volatility
| PPBT volatility | |
|---|---|
| PPBT Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PPBT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PPBT's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 10 | Gil Efron | purple-biotech.com |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
Purple Biotech Ltd Fundamentals Summary
| PPBT fundamental statistics | |
|---|---|
| Market cap | US$5.94m |
| Earnings (TTM) | -US$26.39m |
| Revenue (TTM) | n/a |
Is PPBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPBT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$59.00k |
| Gross Profit | -US$59.00k |
| Other Expenses | US$26.33m |
| Earnings | -US$26.39m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PPBT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 11:19 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Purple Biotech Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Bodnar | H.C. Wainwright & Co. |